ReviewFrontiers in immunology2026
The shifting balance: innate lymphoid cell plasticity in chronic gut diseases.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Innate lymphoid cells (ILCs), as core components of innate immunity, coordinate mucosal immune defense and homeostasis through their functional plasticity. They exhibit functional diversity in the intestine and display a complex dual role in intestinal diseases, which is closely associated with their phenotypic transformation and functional reprogramming. Current studies have demonstrated that ILCs play critical roles in various chronic intestinal diseases, including autoimmune intestinal disorders, chronic infectious intestinal inflammation, and colorectal cancer. However, the specific functions and reprogramming mechanisms of ILC subsets remain controversial across different types of intestinal diseases. This review provides a comprehensive overview of current research on the mechanisms of ILCs in chronic intestinal diseases, aiming to advance the development of immunotherapeutic strategies targeting ILC reprogramming and offer novel insights into the prevention and treatment of intestinal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.